07/09/2026
Still Healing - From the Diary of a BIND patient
Benzodiazepine-induced neurological dysfunction (BIND)
Before the beginning
I think the story starts earlier than most people would guess. With a childhood that was more stressful than it looked from the outside, a mattress that should have been thrown out years before it was, and a body that started reacting to ordinary things - chlorine, scents, cleaning products - around age eleven or twelve and never really stopped. I don't know for certain how much of what came later traces back to that. I only know that by the time I was on SSRIs and then benzodiazepines, I wasn't starting from a fully resilient baseline.
The crash
By October 2020, something in me broke in a way I hadn't experienced before. Head pain that felt like my brain was on fire — pulsing, trembling, every neuron firing without permission. White light flooding my vision for hours. A body so hypersensitive that a video game, a cup of coffee, or getting excited about a sports game could set it off. Adrenaline surges that felt like panic attacks even when I was, on the surface, calm. I stopped being able to tolerate exercise, or heat, or most food. I lived for a while on beef, bread, potatoes, and butter, because almost everything else lit my body up.
I want to be honest that there was a point where the pain made me feel like I couldn't keep going. I reached out for help anywhere I could find it, including to people who weren't my doctors, because my doctors had run out of answers.
A treatment that made it worse
In August 2022, out of sheer desperation, I flew to Mexico for a mesenchymal stem cell infusion. It didn't help. It made things dramatically worse — the head pain came back harder and more often, the adrenaline surges intensified, and my sensitivity to ordinary chemicals and pollen got so bad I couldn't go outside. That's when I emailed Surjo Banerjee, the email that started this whole next chapter, half medical history, half a plea for someone, anyone, to tell me what was happening to me.
Trying again
In February 2023, I traveled to Somata Genesis India for a two-week protocol — intrathecal and cerebrovascular administration of neural cells and growth factors, daily physiotherapy, a strict diet, supplements. I went in with my eyes open that this wasn't an approved, mainstream treatment. I did it because I was out of other options I could live with.
The years since
What followed hasn't been a straight line, and I want to record it honestly rather than as a triumph story.
Starting in November 2023, something shifted — a real surge in what felt like testosterone, rapid weight and strength gains, a libido and drive I hadn't felt in years. It came with a cost: my emotions went flat again just as the physical changes accelerated, and for stretches of 2024 I felt more numb than hopeful, even while my body kept changing in ways I couldn't fully explain — my shoulders felt broader, my face felt different, clothes stopped fitting the way they used to. Surjo described a picture involving hormones and the neuroendocrine system to make sense of it for me, and I've come to describe the pattern to myself as waves: a surge, a rough patch while my system adjusts, then a slightly higher baseline once it settles. That's just the language I use for it. I don't know how much of it is established versus what I was living through, and I think that's worth being honest with myself about.
My father died in February 2024, in the middle of one of those rough patches, which made an already hard year harder.
Through 2024 and into 2025, things kept moving in a direction I was grateful for even when it didn't feel linear: more days with some flicker of interest or motivation, then months of flatness again, then more. By January 2025 the testosterone-linked feelings became more consistent than they'd ever been. I started, for the first time in years, being able to feel physically relaxed — not just still, but actually at ease — which I hadn't experienced since around 2017 or 2018.
The two changes I'm most grateful for came late: sometime in the summer of 2026, my sleep schedule, which had been stubbornly, severely nocturnal for years despite every attempt to fix it, became adjustable again, almost overnight. And my baseline anxiety, which had been sky-high for as long as I could remember, dropped to the lowest it's been in over twenty years.
Where I am now
As of this September, I'm not going to pretend I'm fully recovered. My autonomic system is much better than it was, but not fully normalized. I still don't have the sustained energy and cognitive stamina I'd need to go back to full-time work, and I don't know exactly when I will. What I do have is a nervous system that feels sturdier, an anxiety baseline I haven't known since I was a kid, and a body that keeps surprising me, for better and — sometimes — in ways I still can't explain.
A note to myself
A couple of things from these years are still open questions I want real answers to, independent of anything to do with this treatment: the petechiae that's shown up on and off since I started SSRIs, and the real possibility, given my family history, that I should get proper genetic counseling about the Alzheimer's question rather than carrying the worry around unanswered. I'm writing that down here so I don't let it slide.
This is where I am. Still healing. Still not entirely sure what to make of some of it. Genuinely further along than I let myself hope for three years ago.
Case Study
This case study details the longitudinal recovery of a 22-year-old male presenting with severe central nervous system (CNS) neuroinflammation, autonomic dysfunction, and persistent hypersensitivity. The etiology was linked to neurotoxic damage from benzodiazepine and SSRI exposure, which was subsequently exacerbated by an adverse immunogeneic reaction to a mesenchymal stem cell (MSC) intervention in Mexico.
Following a targeted regenerative and metabolic protocol at Somata Genesis in early 2023, the patient experienced profound physiological and neurological shifts. Recovery has been characterized by a distinct ‘surge and plateau’ integration model, where the brain cyclically tests higher neurochemical and hormonal thresholds—leading to temporary symptom irritation followed by stabilized, elevated baselines. Over a three-year period, the patient has demonstrated neuroendocrine improvements, dramatic late-pubertal skeletal and vocal development, the correction of severe circadian dysregulation, and vastly improved autonomic stability. The case highlights the remarkable plasticity of the CNS and underscores the necessity of personalized, supportive biological frameworks in resolving severe iatrogenic neurotoxicity.
Patient Profile & Initial Presentation
Demographics: 22-year-old European male at initial presentation.
Primary Condition: Severe central nervous system (CNS) neuroinflammation, onset October 1, 2020.
Etiology: Neurological and autoimmune damage secondary to benzodiazepine and SSRI exposure/withdrawal.
Pre-Existing Factors: Early childhood stress, severe mold exposure, and ammonia inhalation during critical brain development; family history of early-onset Alzheimer's disease.
Clinical History & Prior Interventions
In August 2022, the patient received a mesenchymal stem cell (MSC) intervention (250M IV / 50M intrathecal) in Mexico.
This treatment induced a severe immunogenic regression, triggering unrelenting head pain, surging adrenaline, elevated anxiety, and extreme environmental hypersensitivity.
Baseline Symptomatology (Prior to Somata Genesis Treatment)
Neurological & Pain: Excruciating, high-frequency pulsing head pain aggravated by minimal movement, severe tinnitus, nerve pain, and inner vibrations.
Visual & Sensory: White, high-frequency pulsing lights covering visual fields for hours; extreme photophobia and chemical sensitivities.
Autonomic & Metabolic: Severe heat/exercise intolerance causing tachycardia and drops in blood pressure; low blood sugar sensations despite normal blood glucose levels.
Psychiatric & Cognitive: Severe depression, emotional blunting, anhedonia, exaggerated startle reflexes, and cognitive deficits.
Somata Genesis Protocol
Treatment Timeline: Intensive treatment completed in India over a two-week period (February 15 – March 1, 2023).
Neural Cell Transplant Procedural Protocol: Cerebrovascular and intrathecal administrations of neural and other multipotent cells and growth factors over a period of 2 weeks, along with daily physiotherapy.
Supportive Metabolic Regimen: High protein, whole eggs, low carbohydrates, Vitamin D3, Omega-3/Krill oil, binders and Vitamin C.
Longitudinal Recovery & Integration Dynamics
Phase 1: Initial Neuroendocrine Shift (Nov 2023 – Jan 2024)
Hormonal & Physical Changes: Massive natural surge in testosterone output accompanied by rapid muscle growth. Weight peaked at 157 lbs before settling to a stable baseline of 142 lbs as neuroendocrine strain balanced out.
Neuromuscular Activity: Significant spasticity, muscle twitches, and spontaneous musical auditory processing during sleep transition states.
Phase 2: Structural Expansion & Neurogenesis (Feb 2024 – Aug 2024)
Skeletal & Facial Growth: Onset of late-pubertal structural expansion, including shoulder broadening and lengthening of facial bones.
Neural Rewiring: Alternating periods of exhaustion and intense dopamine surges, lucid dreaming, and painless brain rewiring sensations.
Phase 3: Dynamic Integration & Autonomic Stabilization (Sept 2024 – Sept 2026)
Circadian Rhythm Correction: Marked physiological shift during Summer 2026; circadian rhythm transitioned from severe dysregulation to natural, unprompted morning awakenings without an alarm.
Ongoing Morphological Progress: Continuous facial bone remodeling and ongoing vocal deepening (late puberty dynamics).
Autonomic & Exercise Capacity: Vastly improved exercise tolerance and autonomic stability, though full autonomic normalization remains an active, ongoing recovery process.
Physiological Integration Model (Surge & Plateau Pattern)
Recovery follows a distinct cyclical pattern occurring every few months:
Neuroendocrine Surge: The central nervous system tests higher baseline thresholds of testosterone, dopamine, and drive.
Symptom Irritation: The acute increase in neurochemical capacity temporarily irritates baseline symptoms and causes transient neurological fatigue.
Baseline Reset: As the broader brain builds tolerance to these higher neurochemical levels, symptoms settle, leaving a permanently elevated, higher baseline for dopamine, emotional depth, and personality expression.
Current Clinical Status (As of September 2026)
The patient exhibits a significantly stronger and more robust nervous system. Autonomic normalization and exercise tolerance continue to steadily improve. Daily baseline dopamine, full emotional range, and overall energy levels are actively rebuilding. While ongoing work capacity and cognitive stamina are still expanding to support a future return to full-time employment, the patient's nervous system demonstrates continuous structural healing and neuroendocrine integration.
Ethical Declaration & Informed Consent
This is not a clinical trial. This subject voluntarily participated in this case study to evaluate the effects of Somata Genesis’s Neural Cell Transplant Protocol on his neuroinflammatory condition, neurotoxicity from CNS medicine exposure, and immunogenic reactions from his prior stem cell therapy in Mexico. We screened this subject for inclusion and captured baseline brain and spine imaging and blood tests. The patient was informed of all the possible risks and limitations of this experimental procedural protocol. We counseled the patient and documented all communication. This case study was conducted under hospital institutional review board oversight by licensed medical professionals and surgeons.
Conclusion
The clinical trajectory of the patient illustrates both the debilitating complexities of pharmaceutical-induced CNS damage and the profound regenerative capacity of the human nervous system. The patient's initial regression following an uncharacterized MSC treatment serves as a critical warning regarding the use of aggressive cellular therapies in an actively excitotoxic and inflamed neural environment. Conversely, ongoing recovery under the Somata Genesis protocol demonstrates that with appropriate metabolic and biological scaffolding, the brain can initiate extensive structural and neuroendocrine repair.
As of September 2026, recovery continues through a dynamic, steady process of neurochemical integration. While the patient's central nervous system is still actively building the cognitive stamina and energy robustness required for full-time employment, the clinical milestones achieved, ranging from continuous morphological growth to the spontaneous normalization of the circadian rhythm, are exceptional. Baseline anxiety is at a twenty-year low, and autonomic resilience continues to expand. This case provides compelling evidence for a cyclical, non-linear model of neuro-repair, offering a highly promising framework for managing and reversing severe central neuroinflammation.
Neural Cell Protocol — Information for Prospective Patients
This sheet is meant to inform, not persuade. It should be read alongside independent medical advice, not in place of it. It does not replace a formal informed-consent process, which should be reviewed with your own treating physicians and, ideally, an independent specialist.
What the treatment involves
The protocol consists of cerebrovascular and intrathecal (spinal fluid) administration of neural and other multipotent cells and growth factors over roughly two weeks, combined with daily physiotherapy and a supportive metabolic regimen (high protein, low carbohydrate, vitamin D3, omega-3, binders, and vitamin C). It has been offered to patients with a range of neurological and neuroinflammatory conditions, especially configured for cases involving benzodiazepine- and SSRI-related nervous system injury.
Hypothesis
This intervention supports repair of neuroendocrine axes (including what we refer to as the HPT axis), promotes neurogenesis, and allows a cascade of downstream hormonal and neurological changes as the body recalibrates. Patients have reported a wide range of effects over months to years following treatment, including changes in mood, sleep, exercise tolerance, and in some reported cases, physical changes such as altered body composition.
This framework is our own clinical model, built from what we've observed across subjects, particularly BIND patients. It has not yet been validated in peer-reviewed, controlled research because of the lack of CNS drug-induced-treatment frameworks and current radiodiagnostic limitations. Some elements, particularly claims of significant skeletal or facial bone growth attributable to hormonal changes well into adulthood, are not supported by current scientific literature about human skeletal development, which holds that primary bone growth concludes by the late teens to early twenties.
What independent science currently says
Benzodiazepine-induced neurological dysfunction (BIND) is a real and increasingly recognized condition. Persistent symptoms following benzodiazepine use, including sensory hypersensitivity, autonomic instability, and cognitive effects, are documented in peer-reviewed research. This is a legitimate basis for the symptoms many patients bring to us.
Adult neurogenesis in the human hippocampus is a genuine but still-debated area of research; evidence exists on multiple sides, and its clinical relevance to any specific patient's treatment outcome is not established.
Late-adulthood skeletal or facial regrowth driven by hormonal change is not a recognized phenomenon in the endocrinology or orthopaedic literature.
Risks
This clinical intervention is carried out under hospital oversight, following patient safety standards and taking precautionary measures. This case does not validate stem cell therapies in general. Uncharacterized cell-based interventions carry real, documented risks, including infection, immune reactions, and — in patients who have undergone similar treatments elsewhere, including this case — significant worsening of neurological symptoms rather than improvement. Anyone considering stem cell therapy should know that a bad outcome, including a severe one, is a real possibility, not a remote hypothetical.
Before you decide
Talk to your own treating physicians, including any specialists managing your condition, before pursuing this or any experimental treatment within the country or abroad.
Consider getting an independent second opinion from a clinician.
Ask us directly about our safety record, including any adverse events, clinical and laboratory practices, and verify our medical credentials and regulatory standing rather than relying only on limited public information.
Understand that we cannot guarantee any outcome, and that any recovery may be slow, non-linear, and incomplete.
This patient does not want their identity to be made public; however, they are available to speak to anyone considering this treatment for themselves.
C
